Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Xantos Biomedicine AG, NascaCell and PSF biotech collaborate on cancer drug discovery project

15 Apr 2005 - Xantos Biomedicine AG announced a collaboration with NascaCell IP GmbH and PSF biotech AG. The consortium is set to identify and develop new drugs for the inhibition of tumour angiogenesis, a process by which the growth of blood cells from surrounding tissue into a tumor is induced by a protein released from tumor cells.
 
The collaboration, using an aptamer-based approach, will integrate the innovative technology platforms of the three companies, combining Xantos' target discovery expertise and small molecule screening technology, PSF Biotech's protein production and crystallisation capabilities and NascaCell's aptamer technology for target validation and drug discovery. By combining the expertise of the three partners, the consortium called PADDION aims to develop new drugs with the potential to replace or complement established therapies and will receive initial funding by the BioChancePlus program from the German Federal Ministry of Education and Research (BMBF).